Sugi Predict

Sugi Predict / Compounds / SCHEMBL183035

SCHEMBL183035

SCHEMBL183035

Cn1cnc2c(Cl)nc(Cl)nc21

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 5/20 0.68
▸ YTHDC1 Q96MU7 2/20 0.64
▸ CCNE1 P24864 2/20 0.46
▸ CDK2 P24941 2/20 0.46
▸ CCNE2 O96020 1/20 0.46
▸ P2RX7 Q99572 2/20 0.44
▸ LMNA P02545 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ ADORA2A P29274 1/20 0.40
▸ ADORA1 P30542 1/20 0.40
▸ CCNB1 P14635 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29426225 1.00 CDK1 (0.68) CDK1YTHDC1CCNE1CDK2CCNE2
SCHEMBL31085272 0.87 CDK1 (0.53) CDK1YTHDC1CCNE1CDK2CCNE2
SCHEMBL7289687 0.82 CDK1 (0.51) CDK1YTHDC1CCNE1CDK2CCNE2
SCHEMBL25876344 0.82 CDK1 (0.66) CDK1YTHDC1CCNE1CDK2CCNE2
SCHEMBL30173097 0.81 CDK1 (0.50) CDK1YTHDC1CCNE1CDK2CCNE2
SCHEMBL4378141 0.81 CDK1 (0.50) CDK1YTHDC1CCNE1CDK2CCNE2
SCHEMBL129921 0.81 CDK1 (1.00) CDK1YTHDC1ADORA2AADORA1
SCHEMBL380974 0.81 CDK1 (0.50) CDK1YTHDC1CCNE1CDK2CCNE2
SCHEMBL764036 0.81 CDK1 (0.59) CDK1YTHDC1CCNE1CDK2ADORA2A
SCHEMBL19978922 0.78 CDK1 (0.60) CDK1YTHDC1CCNE1CDK2CCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710199-B Photooxidation reduction catalytic process 深圳湾实验室坪山生物医药研发转化中心 2024-06-28 — — CN claimed
EP-1608317-A4 DIPEPTIDYL PEPTIDASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2006-12-27 — — EP claimed
EP-1608317-A2 DIPEPTIDYL PEPTIDASE INHIBITORS Takeda San Diego, Inc. (US) 2005-12-28 — — EP claimed
US-20050004117-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2005-01-06 — — US claimed
WO-2004087053-A9 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX INC (US) 2004-11-11 — — WO claimed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 — — WO claimed
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 — — US disclosed
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2025-12-25 — — US disclosed
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
US-20250326761-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4634186-A1 2,6,9-TRISUBSTITUTED PURINES Astrazeneca AB (SE) 2025-10-22 — — EP disclosed
EP-1456209-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2004-09-15 — — EP disclosed
WO-2004021979-A2 PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-18 — — WO disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 — — US disclosed
WO-2003051882-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2003-06-26 — — WO disclosed
US-5583137-A Heterocyclic compounds for enhancing antitumor activity PFIZER INC. (US) 1996-12-10 — — US disclosed
EP-0626964-A1 HETEROCYCLIC COMPOUNDS FOR ENHANCING ANTITUMOR ACTIVITY PFIZER INC. (US) 1994-12-07 — — EP disclosed
WO-1993017021-A1 HETEROCYCLIC COMPOUNDS FOR ENHANCING ANTITUMOR ACTIVITY PFIZER, INC. (US) 1993-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004117-A1 Dipeptidyl peptidase inhibitors DPP9, DPP4, DPP3 CDK1 728/4885YTHDC1 4385/4885CCNE1 1291/4885
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF SLC10A1, NR3C2, CYP2C8 CDK1 4166/4885YTHDC1 4615/4885CCNE1 1684/4885
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 CDK1 209/4885YTHDC1 3689/4885CCNE1 464/4885
US-20250326761-A1 sGC STIMULATORS GUCY1A2, PRKG1, GMPS CDK1 3248/4885YTHDC1 2826/4885CCNE1 4220/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 CDK1 72/4885YTHDC1 3839/4885CCNE1 231/4885
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 CDK1 1472/4885YTHDC1 2858/4885CCNE1 3733/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE CDK1 1075/4885YTHDC1 2276/4885CCNE1 2358/4885
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3C2B, PIK3C2A, PIK3R1 CDK1 72/4885YTHDC1 3570/4885CCNE1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.